Author:
Howarth Peter,Bachert Claus,Sousa Ana,Chan Robert
Subject
Immunology,Immunology and Allergy
Reference6 articles.
1. Eosinophil paradox with mepolizumab in chronic rhinosinusitis with nasal polyposis;Lipworth;J Allergy Clin Immunol,2020
2. Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy;Howarth;J Allergy Clin Immunol,2020
3. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis;Gevaert;J Allergy Clin Immunol,2011
4. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial;Bachert;J Allergy Clin Immunol,2017
5. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial;Chupp;Lancet Respir Med,2017